Company
Engimmune Therapeutics AG
- AI
- Biotech
- Founded:
- 2021
- Location:
- Allschwil, Switzerland
Description
Engimmune Therapeutics AG engineers soluble T‑cell receptor (TCR) therapeutics using AI‑guided protein engineering to create multispecific, high‑affinity soluble TCRs for targeting solid tumors and immune‑mediated diseases in preclinical programs.
Related
ImmunocoreImmunocore engineers ImmTAX T cell receptor–based therapeutics to activate or suppress immune responses, advancing bispecific TCR…
Aukera Therapeutics GmbHAukera Therapeutics GmbH develops the first RAPTOR inhibitors, using an AI-driven drug discovery platform and mTOR biology expertise to…
ImmaticsImmatics develops PRAME-targeted immunotherapies, advancing T-cell receptor cell therapies and bispecific molecules such as IMA203 and…
CytovationCytovation develops CyPep-1, a tumor membrane-targeted immunotherapy, using peptide engineering to activate immune recognition and tumor…
Numab TherapeuticsNumab Therapeutics engineers multispecific antibodies, combining antibody engineering and Swiss scientific expertise to build a proprietary…
BIMINI BiotechBIMINI Biotech develops first-in-class small-molecule therapeutics targeting the Wiskott–Aldrich Syndrome protein for oncology and…
FimmCyte AGFimmCyte AG develops targeted immunotherapies that recognize a fibrosis-associated protein to selectively eliminate diseased fibrotic…
XamplaXampla makes Morro™ materials from natural polymers extracted from plants, using patented plant-polymer technology to provide plastic-free,…
LabGenius TherapeuticsLabGenius Therapeutics builds ML-driven discovery and optimisation for therapeutic antibodies, providing the EVA™ platform to design, test…